TRADING UPDATES: Ingenta trades in line; Triple Point Social NAV up
(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Friday and not separately reported by Alliance News:
Read moreWed, 26th Jun 2019 10:49
(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Friday and not separately reported by Alliance News:
Read more(Alliance News) - IQ-AI Ltd on Friday said its subsidiary, Imaging Biometrics LLC, has been granted rare paediatric disease designation by the US Food & Drug Administration for its lead drug candidate, IB-003, or gallium maltolate for the treatment of ATRT.
Read more(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:
Read moreIQ-AI Ltd - Medical services firm and parent company of Wisconsin-based healthcare imaging software firm Imaging Biometrics LLC - Announces placing to raise GBP300,000 gross proceeds via the issue of 20.0 million new shares at a price of 1.5p each. The issue price represents a discount of 32% to the company's Wednesday closing price of 2.2p. The placing includes a broker option for existing shareholders for up to 6.7 million new shares, which would raise an additional GBP100,000. Admission of the new placing and broker option shares is expected to occur on or around March 1.
Read more(Alliance News) - IQ-AI Ltd on Friday said its subsidiary Imaging Biometric LLC will modify and resubmit its application to the US Food & Drug Administration.
Read moreIQ-AI Ltd - St Helier, Jersey-based medical services firm - Says that Imaging Biometrics LLC, a wholly-owned subsidiary of IQ-AI, has been given a USD100,000 grant by the Musella Foundation For Brain Tumor Research & Information Inc. Explains that the grant will help to support the launch of an intermediate group expanded access programme, which is focused on giving brain tumour patients access to oral gallium maltolate, outside of an ongoing Phase One clinical trial at the Medical College of Wisconsin. The grant will be used to facilitate the expanded access programme, including writing and submitting the study protocol, patient screening and on-boarding.
Read more(Alliance News) - IQ-AI Ltd shares fell on Wednesday, after it said its subsidiary Imaging Biometrics LLC is launching an intermediate population cohort expanded access programme for oral gallium maltolate.
Read more(Alliance News) - IQ-AI Ltd on Tuesday said the US Food & Drug Administration has granted 'fast-track" designation for oral gallium maltolate, which is its subsidiary Imaging Biometrics LLC's therapeutic for the treatment of adult patients with relapsed or refractory glioblastoma.
Read more(Alliance News) - IQ-AI Ltd on Tuesday reported positive results from Phase 1 of an on-going study for its investigational monotherapy oral gallium maltolate.
Read more(Alliance News) - IQ-AI Ltd on Wednesday said its wholly-owned subsidiary Imaging Biometrics LLC has submitted a paediatric rare disease request to the US Food & Drug Administration for its gallium maltolate therapy.
Read moreIQ-AI Ltd - St Helier, Jersey-based medical services firm focused on cancer treatment - Notes its wholly-owned subsidiary, Imaging Biometrics LLC (IB), has announced the results of a "landmark" study. Says the study represents the first large-scale characterization of the invasive tumour margins of high-grade glioma using multi-regional genomic/transcriptomic sequencing with spatially matched MRI measurements in glioma. High-grade glioma is a deadly brain cancer. Explains that Imaging Biometrics' IB Neuro's dynamic susceptibility contrast magnetic resonance imaging software was central to the study.
Read moreIQ-AI Ltd - St Helier, Jersey-based medical services firm focused on cancer treatment - Wholly-owned subsidiary Imaging Biometrics LLC is granted an orphan drug designation from the US Food & Drug Administration for gallium maltolate for the treatment of atypical teratoid rhabdoid tumour. Notes this is the second orphan designation granted to gallium maltolate this year.
Read more(Alliance News) - IQ-AI Ltd on Friday noted that studies by its subsidiary Imaging Biometrics LLC validated the dosing approach of Imaging's MRI-focused IB Neuro.
Read more(Alliance News) - IQ-AI Ltd on Friday said its wholly-owned subsidiary Imaging Biometrics LLC has signed a deal with GE HealthCare Technologies Inc.
Read more(Alliance News) - IQ-AI Ltd on Thursday announced a slightly lower loss for the six months to June 30, as revenue was up and administrative expenses were lower.
Read more